

Therapeutic potential of glial cell line-derived neurotrophic factor and cell reprogramming for hippocampal-related neurological disorders

<https://doi.org/10.4103/1673-5374.320966>

Date of submission: October 31, 2020

Date of decision: January 26, 2021

Date of acceptance: April 8, 2021

Date of web publication: August 4, 2021

Priscila Chiavellini, Martina Canatelli-Mallat, Marianne Lehmann, Rodolfo G. Goya, Gustavo R. Morel*

Abstract

Hippocampus serves as a pivotal role in cognitive and emotional processes, as well as in the regulation of the hypothalamus-pituitary axis. It is known to undergo mild neurodegenerative changes during normal aging and severe atrophy in Alzheimer's disease. Furthermore, dysregulation in the hippocampal function leads to epilepsy and mood disorders. In the first section, we summarized the most salient knowledge on the role of glial cell-line-derived neurotrophic factor and its receptors focused on aging, cognition and neurodegenerative and hippocampal-related neurological diseases mentioned above. In the second section, we reviewed the therapeutic approaches, particularly gene therapy, using glial cell-line-derived neurotrophic factor or its gene, as a key molecule in the development of neurological disorders. In the third section, we pointed at the potential of regenerative medicine, as an emerging and less explored strategy for the treatment of hippocampal disorders. We briefly reviewed the use of partial reprogramming to restore brain functions, non-neuronal cell reprogramming to generate neural stem cells, and neural progenitor cells as source-specific neuronal types to be implanted in animal models of specific neurodegenerative disorders.

Key Words: aging; Alzheimer's disease; cell reprogramming; epilepsy; gene therapy; glial cell line-derived neurotrophic factor; hippocampus; major depression

Overview

Functional neurological disorders such as Alzheimer's disease (AD), epilepsy, and depression are related to hippocampal dysfunction. In this context, research and development of novel therapeutic tools like gene therapy and cell reprogramming strategies may open new avenues for the treatment of these devastating pathologies. Since glial cell line-derived neurotrophic factor (GDNF) remains a valuable therapeutic gene in the hippocampus, we summarized the role of this molecule in the pathophysiology of these diseases. We highlighted the most salient reports focusing on GDNF gene therapy as a neuroprotective strategy for hippocampal dysfunction. In order to potentiate GDNF gene therapy and cell reprogramming for neurological diseases by combining them in the future, we have revised and updated the studies reporting the regenerative effects of cell reprogramming in the brain, which is a novel and promising approach.

Search Strategy and Selection Criteria

Studies cited in this review published from 1962 to 2020 were searched on the <https://pubmed.ncbi.nlm.nih.gov> database using the following keywords: GDNF, aging, Alzheimer's disease, epilepsy, depression, gene therapy, cell reprogramming, Yamanaka genes.

Role of Glial Cell Line-Derived Neurotrophic Factor in Aging and Hippocampal-Related Neurological Disorders

GDNF biology

GDNF was identified and purified from the B49 glioma cell line based on its ability to promote survival, neurite outgrowth, cell size, and dopamine uptake of dopaminergic neurons in dissociated rat mesencephalic cultures (Lin et al., 1993). GDNF is the founding member of the GDNF family of neurotrophic factors, which additionally includes three other structurally related members: neurturin, persephin, and artemin (Kotzbauer et al., 1996; Baloh et al., 1998; Milbrandt et al., 1998). The members of the GDNF family belong to the transforming growth factor beta superfamily. GDNF is active as a glycosylated disulfide-bonded homodimer, which triggers a signal through a multicomponent receptor complex containing the transmembrane RET tyrosine kinase and the GDNF family receptor α (GFR α) (Durbec et al., 1996; Trupp et al., 1999). Four GFR α -like receptors have been identified (i.e., GFR α 1 to 4), each with different selectivity and specificity for each of the four members of the GDNF neurotrophic family. The GDNF/GFR α 1/RET triggers both the Ras/MAP kinase and phosphoinositide 3-kinase/AKT tyrosine kinase pathways (Ibáñez, 2013). The anchoring to the plasma membrane of these receptors depends on lipid linkage, GPI-anchor partition

Biochemistry Research Institute of La Plata (INIBIOLP)-Histology and Embryology B, School of Medical Sciences, National University of La Plata (UNLP), La Plata, Buenos Aires, Argentina

*Correspondence to: Gustavo R. Morel, PhD, gustavmorel@med.unlp.edu.ar.
<https://orcid.org/0000-0001-7698-7014> (Gustavo R. Morel)

Funding: This work was supported by grant #PICT16-1070 from the Argentine Agency for the Promotion of Science and Technology (ANCYPT) to GRM.

How to cite this article: Chiavellini P, Canatelli-Mallat M, Lehmann M, Goya RG, Morel GR (2022) Therapeutic potential of glial cell line-derived neurotrophic factor and cell reprogramming for hippocampal-related neurological disorders. *Neural Regen Res* 17(3):469-476.

Review

into lipid rafts, which modulates the intensity and duration of RET signaling (Paratcha and Ibanez, 2002). In addition, GFR α receptors can become independent of RET and act in a soluble form (trans-signaling) when cleaved from the plasma membrane by phospholipases (Paratcha et al., 2001). The third member of this multi-component receptor is the neural cell adhesion molecule which signals the activation of Src-like and MAP kinases (Paratcha et al., 2003). Moreover, Syndecan-3 has been described as an alternative signaling receptor of GDNF in the brain without the involvement of the conventional ones mentioned above. The Syndecan-3 chains binding to heparan sulfate activate Src family kinases (Bespalov et al., 2011).

The GDNF family of neurotrophic factors and its receptors constitute one of the main neurotrophic networks of the CNS. Although the GDNF family has been focus mostly on the midbrain of Parkinson's disease animal models, new research has been diverting towards other brain regions such as the hippocampus and its neurological disorders summarized as follows.

Impact of aging on GDNF expression in the hippocampus

Aging is the main risk factor for neurodegenerative disorders. In the rat hippocampus, it may result in decreased neurogenesis, increased astrogliosis and reactive microglia (Morel et al., 2015; Pardo et al., 2017).

In murine models, it has been reported that GDNF is reduced in the cerebral cortex of aged mice (Lee et al., 2000) as well as in the hippocampus of the senescence-accelerated mouse brain (Miyazaki et al., 2003). However, in 6–13-month-old Fisher 344 rats, GDNF expression level significantly increased in the frontal cortex, but no significant change was observed in the hippocampus (Matsunaga et al., 2006). In humans, it has been reported a decrease in the expression levels of GDNF in plasma from patients with mild cognitive impairment (Siegel et al., 2000).

GDNF role in cognition

GDNF and its receptors are expressed within the temporal lobe, particularly in the pyramidal and granule cells of the hippocampus. However, in the normal mature brain GDNF is mainly produced in neurons (Marco et al., 2002). GDNF and GFR α -1 are expressed in both neurons and astrocytes (Nicole et al., 2001). The GFR α 1 synaptic localization was determined in neuronal cell cultures, indicating the role of GDNF/GFR α 1 in synapse formation (Ledda et al., 2007).

The suggestion that endogenous GDNF may be critical for cognitive abilities derives from a study in mice subjected to a deletion of the GDNF gene. These animals showed a reduction in GDNF mRNA and selective impairment of their performance in the spatial memory in the Morris water maze (Gerlai et al., 2001).

A recent study performed in conditional mutant mice lacking GFR α 1 in the newborn granular cell population demonstrated significant pattern separation impairment compared to the control group. This mnemonic impairment could be explained by the deficit observed in dendrite outgrowth and the lack of mature spines, which would lead to an altered integration of newborn hippocampal cells (Bonafina et al., 2019).

A first genetic study demonstrated that the lack of function of GFR α 2 in mice resulted in significant impairment in the performance of the animals in three different tests of learning and memory. The mutant mice exhibited reduced contextual memory and context discrimination in contextual fear conditioning and showed impaired behavioral flexibility in spatial learning, and decreased retention of conditioned taste aversion memory tests (Vöikar et al., 2004).

These findings demonstrated that GDNF and GFR α family

receptors play a crucial role in cognition and compromise the hippocampal integrity on neurodegenerative diseases associated with cognitive decline (Scheff et al., 2006; McKinnon et al., 2009). We summarized the most relevant findings of GDNF role in AD, epilepsy, and major depressive disorders.

Alzheimer's disease

AD, a neurodegenerative pathology with high prevalence and morbidity is accompanied by progressive memory deficit, cognitive impairment, and dementia (Querfurth and LaFerla, 2010). At the molecular level, AD is characterized by extracellular deposition of amyloid beta (A β), the formation of neurofibrillary tangles, and tau hyperphosphorylation. Neurodegeneration involves selective neuronal death into vulnerable brain regions, in particular the hippocampus and cerebral cortex, where apoptosis may play a role in the process (Honig and Rosenberg, 2000).

At present, there are no effective therapies to reverse its progression. Thus, efforts center on searching molecules as clinical markers for early detection or therapeutic strategies. In line with this, clinical studies reveal that GDNF level increased in cerebrospinal fluid and its serum concentration decreased in the early stages of AD (Straten et al., 2011). Another study found increased GDNF levels in plasma of AD patients (Markstainer et al., 2011). Nevertheless, in the postmortem middle temporal gyrus of AD patients, it was found that the expression pattern of novel human GDNF isoforms was down-regulated (Airavaara et al., 2011). In the same line, a study found the serum GDNF levels significantly reduced in mild cognitive impairment and AD patients (Forlenza et al., 2015).

Temporal lobe epilepsy

The most common epilepsies in adults originate focally in structures such as hippocampus, EC, or amygdala and are named temporal lobe epilepsies (TLE) (Yilmazer-Hanke et al., 2000; Lévesque et al., 2013). The hippocampal Cornu Ammonis (CA) region and the dentate gyrus (DG) are involved in seizure generation and hippocampal sclerosis (Reyes-Garcia et al., 2018). Induction of an epileptic status with kainic acid (KA) or pilocarpine produces spontaneous seizures that continue for the rest of the animal's life. Epileptic rodents show patterns of neuronal loss and synaptic reorganization in the hippocampus, similar to those of patients with TLE. One of the plastic changes is related to an increase in neurogenesis in DG, but these new neurons present aberrant network reorganization (Bengzon et al., 1997; Parent et al., 1997).

On the other hand, kindling also induces structural changes in the brain that can be permanent, such as the sprouting of the DG Mossy fiber pathway and astrocyte hypertrophy with an accompanying increase in hilar volume in the DG (Cavazos et al., 1990, 1991, 1994; Adams et al., 1997, 1998).

Brain damage in animal models of epilepsy generates a rapid cellular response traduced in both immediate early genes and neurotrophic factors genes expression (Sperk et al., 1994).

An association between GDNF expression in the hippocampus and epilepsy is suggested by the observation that seizures increase the levels of GDNF mRNA and protein (Humpel et al., 1994; Kokaia et al., 1999) and by the fact that seizures can be suppressed by local overexpression of GDNF into the hippocampus (Yoo et al., 2006; Kanter-Schlifke et al., 2007, 2009). A recent finding on the contribution of miRNAs to the pathophysiology of epilepsy demonstrated that GDNF is silenced by miR-451 in a KA model causing neuronal damage. Moreover, GDNF overexpression contrasts miR-451 effect (Weng et al., 2020).

Mood disorders

Mood disorders are a group of psychiatric illnesses that can

simultaneously affect emotions, energy, and motivation. Several imaging and post-mortem studies in patients with mood disorders provides evidence for glial reduction in total volume and cell density/size of particular areas such as prefrontal cortex, hippocampus, and amygdala (Öngür et al., 1998; Manji et al., 2001; Rajkowska, 2002).

The two most prominent examples are major depressive disorder (MDD) and bipolar disorder. MDD is characterized by a constellation of symptoms affecting mood, anxiety, neurochemical balance, sleep patterns, and circadian and/or seasonal rhythm entrainment.

MDD is primarily treated with antidepressants. Most of the antidepressants are known to inhibit serotonin and/or noradrenaline reuptake; however, the efficacy of these antidepressants cannot be solely explained by their actions on the monoaminergic system. Accumulating evidence from animal studies indicates that the changes of gene expression and signal transduction related to neuronal and glial plasticity and adaptations after chronic antidepressant treatment are important for the therapeutic effect of antidepressants (Duman, 2004). Regarding neuronal plasticity, chronic antidepressants increase DG neurogenesis through an increment in cell proliferation independently of any changes in cell survival (Malberg et al., 2000). Thus, one of the major roles of astrocytes is the production of neurotrophic/growth factors, which are crucial in the process of neural plasticity (Allen et al., 2009). It has been suggested that neurotrophic factors as GDNF, which are potent regulators for neuronal and glial plasticity, might be involved in the effect of antidepressants. Clinical studies reported that total GDNF levels in whole blood from patients with mood disorders were significantly lower than those in healthy control subjects (Takebayashi et al., 2006). Previous studies have demonstrated that several different classes of antidepressants significantly increased GDNF mRNA levels triggered by monoamine-independent pathway in both rat C6 astroglial cells and rat primary cultured astrocytes, but not in primary cultured neurons (Hisaoka et al., 2007; Katijani et al., 2015). More recently, both clinical and preclinical studies have confirmed that increased production of GDNF upon treatment with antidepressants is believed to play an important role in their therapeutic effect (Zhang et al., 2008; Uchida et al., 2011; Lin et al., 2015).

Gene Therapy with Glial Cell-Line-Derived Neurotrophic Factor for Neurological Disorders

Gene therapy concepts and upgrade

Gene therapy has undergone a remarkable advance in the improvement of gene delivery and expression as well as in safety, cell-type specificity, and regulability by small molecules (Zhang et al., 2012; Simonato et al., 2013). Gene transfer to the CNS has significant challenges due to the relative inaccessibility of both the brain and spinal cord. A relevant obstacle is the blood-brain barrier (BBB), which prevents gene vectors from reaching their therapeutic targets within the CNS. There are some approaches to overcome this problem; one of them is the use of osmotic solutions to disrupt of the BBB. Currently, mannitol solutions disrupt the BBB transiently and reversibly by shrinking endothelial cells and opening the tight junctions (Cosolo et al., 1989). Another approach consists of intranasal delivery, which provides direct absorption of the molecules through the trigeminal and olfactory pathways from the nasal cavity. This possesses the advantage of the direct entrance, low doses, and rapid action in the brain (Erd et al., 2018).

On the other hand, gene therapy offers unique advantages for the long-term delivery of neurotrophic factors to specific CNS regions affected by neurodegenerative processes. Non-viral gene delivery vehicles, such as naked DNA, RNA, liposomes,

and nanoparticles, can harbor large cargo and possess lower costs than viral systems. Approaching *ex-vivo* encapsulated cell biodelivery (ECB) of a therapeutic agent has so far achieved only low levels of therapeutic gene expression during short periods (Fjord-Larsen et al., 2012; Tornøe et al., 2012; Emerich et al., 2014). ECB consists of therapeutic cells encapsulated in a polymer membrane, which has the advantage that the pores in the membrane are large enough to allow the therapeutic agent to diffuse into the surrounding tissue but small enough to protect the cells against immune response. ECB is safe to perform *in vivo* gene therapy in the brain due to the advantage of retrievability.

A large number of genetically modified viruses have proven to efficiently transduce host cells with the therapeutic gene they harbor. Viral vectors commonly used are: helper-dependent adenoviral, adeno-associated, retroviral and herpes-derived vectors, which have specific advantages such as the large size of the gene insert they can accommodate, a wide variety of cells they can transduce, and an extended duration of transgene expression (Simonato et al., 2013).

In line with this, we engineered a regulatable Tet-off system which consists in two adenovectors: the first adenovector harbors the cDNA for rat GDNF and the *Aequorea victoria* Green Fluorescent Protein (GFP) controlled by murine Cytomegalovirus promoter. The second adenovector harbors the tetracycline transactivator protein gene controlled by the murine Cytomegalovirus promoter, which represses gene expression conditioned by the presence of a tetracycline analog, doxycycline (DOX) (Coll et al., 2020). Regarding *in vivo* gene therapy (e.g., injection in the coordinates of CA1 dorsal hippocampus; **Figure 1**), gene expression silencing is achieved by means of a non-invasive procedure, addition to or removal of DOX from the drinking water. Indeed, a safer and more sophisticated approach would be to construct a helper-dependent adenoviral vector harboring GDNF and GFP genes under the tetracycline regulatory system (Lehmann et al., 2019).




Figure 1 | *In vivo* silencing of regulatable two-vector system in the rat hippocampus.

(A) Microphotography of a single pyramidal neuron in the CA1 pyramidal layer transduced with the recombinant adenoviral vector harboring green fluorescent protein. (B) Hippocampal coronal section from a rat injected with the regulatable two-vector system. Notice that absence of transduced cells in the CA1 pyramidal layer. The addition of DOX in the drinking water represses GFP expression. Unpublished data.

GDNF against age-related cognitive deficit

The first therapeutic report was performed in aged-impaired Fisher 344 rats, and it comes from the intracerebroventricular administration of the GDNF peptide that significantly improved spatial learning in the cue version of Morris water maze (Pellemounter et al., 1999).

Afterthought, GDNF was infused in the striatum of 2-month-old Sprague-Dawley rats for 28 days. In this work, new cells were identified by light and electron microscopic immunostaining. GDNF significantly increased cell proliferation in the hippocampus by 78%, showing evidence that this molecule increased neurogenesis in the hippocampus of adult rats (Chen et al., 2005).

Review

The first gene therapy approach derives from an injection of a lentiviral vector harboring GDNF gene in the CA1 dorsal hippocampus of aged-impaired Fisher 344 rats. The over-expression of GDNF in hippocampal astrocytes improved spatial cognitive performance demonstrated by an enhancement of memory retention of the platform location in the test probe trials (Pertusa et al., 2008).

GDNF treatment in animal models of Alzheimer's disease

One of the first studies, performed in a rabbit model of AD induced by aluminum complexes, showed that the GDNF administration can protect against AD-like changes (Ghribi et al., 2001). A recent report in a 7-month-old transgenic mouse model of AD (3xTgAD) has shown that GDNF was down-regulated and this condition was reverted after 6 months of voluntary exercise (Revilla et al., 2014a). Additionally, it has been reported that GDNF gene therapy using a lentiviral vector in 10-month-old 3xTg-AD mice for 6 months showed an improvement in learning and memory (Revilla et al., 2014b).

GDNF for temporal lobe epilepsy

The first study to demonstrate that gene therapy reverses status epilepticus in rats was conducted by Yoo and collaborators. In this work, a recombinant adenoviral vector encoding for GDNF was injected into the hippocampus 7 days prior to KA injection in rats. 3 days after injection of KA, behavioral assessment resulted in the suppression of seizure behaviors and protection of the GAD-67 neurons against KA-induced cellular damage and alteration (Yoo et al., 2006).

In another gene therapy approach, Kanter-Schlifke and collaborators used a recombinant adeno-associated viral (rAAV) vector-based GDNF. Researchers showed that GDNF suppresses seizures in two models of TLE. First, when rAAV-GDNF was injected prior to hippocampal kindling, the number of generalized seizures decreased, and the prolongation of behavioral convulsions in fully kindled animals was prevented. Second, injection of rAAV-GDNF after kindling increased the seizure-induction threshold. Finally, rAAV-GDNF decreased the frequency of generalized seizures during the self-sustained phase of status epilepticus (Kanter-Schlifke et al., 2007).

In a subsequent study in rats, ex-vivo gene therapy employing ECB devices containing genetically modified cells that can release GDNF showed seizure suppression in the hippocampus of kindled rats. However, the optimization of the amount of GDNF released by ECB devices seems to be essential to obtain an antiepileptic effect, with a moderate increase in delivered GDNF levels appearing to be more beneficial (Kanter-Schlifke et al., 2009).

Another approach using ECB-GDNF implanted unilaterally into the seizure focus in the hippocampus of KA epileptic rats effectively decreased the number of spontaneous and recurrent seizures in epileptic rats (Nanobashvili et al., 2018).

Finally, long-term gene therapy with ECB-GDNF implanted directly into the hippocampus of pilocarpine-induced epileptic rats revealed that GDNF reduced seizure frequency by 75% within 2 weeks after treatment and by 93% after 3 months of treatment (Paolone et al., 2019).

Cell Reprogramming for Neurological Disorders

Epigenetics and cell reprogramming

Epigenetic marks refer to changes in gene expression due to reversible covalent modifications without altering the DNA sequence. They can be transmitted to the next generation but are susceptible to environmental modifications, explaining the clinical heterogeneity which confronts traditional genetics (Wu et al., 2001; Urduingio et al., 2009). These epigenetic marks regulate DNA replication, gene expression, and DNA damage responses in not only physiological but also pathological

conditions (Portela et al., 2010).

Cell reprogramming is the conversion of cells from one identity to another. For a long time, cell fate was considered irreversibly determined. It used to be explained by Waddington's epigenetic landscape, in which pluripotent cells were found on top of a hill and descended irreversibly into a valley, which represented their differentiation, an energetically stable state from which they were not able to escape.

In 1960, the first finding challenging this dogma emerged, when John Gurdon achieved the development of a complete organism by inserting the nucleus of a tadpole gut cell into UV-enucleated eggs (Gurdon, 1962). This study and others indicated that cell fate was reversible, and that the cellular nucleus in more late stages of development retained the information necessary to directly develop the different cell types of an individual (Davis et al., 1987; Campbell et al., 1996).

In 2006, Yamanaka and Takahashi overexpressed the Oct-4, cMyc, Klf-4, and Sox2 transcription factors, now also known as Yamanaka factors, in mouse fibroblasts (Takahashi and Yamanaka, 2006; Lehmann et al., 2019). These cells acquired the phenotype of blastocyst-like cells and were named induced pluripotent stem cells (iPSC). From an iPSC, they could be differentiated into any type of cell of any tissue belonging to the three germ layers of a natural embryo. Since then, iPSCs have established cell reprogramming as a strategy with considerable potential for the diagnosis and therapy of different diseases, including those in the field of neurodegeneration.

Cell reprogramming for the treatment of Alzheimer's disease

In 2009, transplantation of neural precursors into a rat model of AD had been shown to promote improvements in the animal's behavior. With the advent of iPSC technology, the possibility of using neural stem cells derived from iPSCs as cell therapy in brain-related diseases arose (Moghadam et al., 2009; Tincer et al., 2016). Since then, various approaches have been developed to obtain induced neural stem cells, which are promising cells since they give rise to different neuronal and glial cell types, in addition to being expandable *in vitro* by several passages.

One strategy used to obtain neural precursors was the pluripotency factor-mediated direct reprogramming, in which pluripotency genes are expressed transiently, by manipulating the epigenetically unstable state of cells and leading it towards the phenotype, in this case, of neural precursors (Kim et al., 2011; Winiiecka-Klimek et al., 2015; Capetian et al., 2016; Connor et al., 2018). Other emerged strategies can be encompassed in transdifferentiation, in which neural precursors were obtained by direct differentiation of fibroblasts through specific transcription factors or miRNAs (Lujan et al., 2012; Yang et al., 2017).

Cell reprogramming to patient-specific cells of interest allows the study of the cellular phenotype of diseases that otherwise would be inaccessible. Through *in vitro* modeling, it is hoped to achieve the development of specific drugs for their treatment (Mertens et al., 2016).

In 2011, induced neuronal cells were obtained from the transdifferentiation of human fibroblasts with the transcription factors Brn2, Ascl1, and Myt1 in combination with the factor NEUROD1. These cells possessed the morphology of mature neuronal cells (Pang et al., 2011).

More specifically in Alzheimer's modeling, skin fibroblasts from patients with familial AD have been converted to induced neuronal cell through a cocktail of seven chemicals, obtaining the same morphology, electrophysiology, and gene expression

profile as iPSC-derived induced neuronal cells. Interestingly, these cells showed increases in the extracellular level of A β ₄₂ and the A β ₄₂/A β ₄₀ ratio (Hu et al., 2015).

Fibroblasts from patients with familial and sporadic AD have also been transduced with Yamanaka factors, reprogrammed to iPSC, then differentiated to neural progenitor cells NPCs and subsequently to neurons with specific media. These neurons exhibited higher levels of A β , phospho-tau, and aGSK-3b than healthy human controls (Israel et al., 2012). These and other studies of AD modeling from iPSC have been recently reviewed, demonstrating the usefulness of cell reprogramming, and opening new possibilities for drug discovery research (Rowland et al., 2018; Hawkins and Duchon, 2019; Raman et al., 2020).

Regarding treatment, in a murine animal model expressing 5xFAD in order to increase the number of astrocytes, reactive glial cells were reprogrammed to neurons using the transcription factor NEUROD1, as a prospective strategy for the recovery of the neuronal loss (Guo et al., 2014). Furthermore, the induction of reactive glial cell-derived neurons by direct reprogramming using miRNAs demonstrated improvements in spatial memory and alternation of a mouse model of Alzheimer's with streptozotocin (Ghasemi-Kasman et al., 2018).

Potential of the Yamanaka factors for the treatment of age-related neurological diseases in mice

Conventional cell reprogramming cannot be implemented *in vivo* as a continuous expression of the OSKM genes *in vivo* induces multiple teratomas (Abad et al., 2013; Ohnishi et al., 2014). This hurdle was overcome by the development of cyclic partial cell reprogramming, a strategy based on the use of multiple cycles of interrupted reprogramming in which OSKM genes expression is turned on briefly and then turned off by means of regulatable promoters. In each cycle the process seems to erase some epigenetic marks of age, sparing the epigenetic marks of cell identity (Lehmann et al., 2019).

In 2016, Ocampo and collaborators demonstrated that cyclic partial reprogramming in OSKM-transgenic progeric mice significantly prolonged their survival and partially rejuvenated some tissues, although it did not rejuvenate the mice themselves (Ocampo et al., 2016). In a more recent study, cyclic partial reprogramming in the hippocampus of middle-aged mice partly reversed the age-dependent reduction in histone H3K9 trimethylation. The treatment elevated the levels of migrating granular cells in the dentate gyrus and also improved mouse performance in the object recognition test (Rodríguez-Matellán et al., 2020).

Recent results have revealed that the Yamanaka genes have a dual behavior when expressed continuously *in vivo*, being regenerative when delivered via viral vectors but lethally toxic when expressed in transgenic mice. Thus, it has been shown that the delivery of the OSK genes by intravitreally injecting a regulatable adeno-associated viral vector type 2 (AAV2) expressing the polycistron OSK can reverse vision deficits in two mouse models (Lu et al., 2020). One of them consists of an experimental model of glaucoma in mice. OSK-AAV2 injection into the vitreous body resulted in DOX-responsive OSK gene expression in around 40% of the retinal ganglion cells and after 4 weeks of continuous OSK expression, an optometric test revealed a significant recovery of vision which was associated with retinal ganglion cells axon regeneration. The same treatment reversed the typical age-related vision impairment in 12-month-old mice. In contrast, DOX-induced expression of OSK in OSK transgenic mice induced rapid weight loss and death, likely due to severe dysplasia in the digestive system (Lu et al., 2020).

Potential of cell reprogramming for the treatment of epilepsy and major depression disorder

It is reasonable to believe that dysregulation of the epigenome would have a significant role in neurological disorders such as TLE and MDD. The reversibility of these changes opens a range of therapeutic possibilities.

Over the past two decades, artificial transcription factors have been developed by fusing a DNA-binding domain to one or more effector domains to allow gene activation and repression (Falahi et al., 2015). The first effector domain was generated by the binding of zinc finger modules (ZF), potentially targeting unique genes by incorporating six ZF that can bind to the 18 base-pair (bp) genomic location (Pavletich et al., 1991).

Researchers have been focused primarily on those transcription factors that can control the genes that drive circuit excitability, seizures, and epilepsy. In line with this, a transcription factor, repressor element silencing transcription factor 1 (REST), has been characterized. REST is strongly induced in the hippocampus in both kainate and pilocarpine models of TLE (Palm et al., 1998). This factor orchestrates many genes known to be involved in neuronal excitability (Roopra et al., 2001).

Regarding MDD, a recent study has implemented selective chromatin remodeling in a region involved in controlling the molecular and behavioral effects of exposure to drugs and stress. The FosB locus was targeted for its role in the pathophysiology of drug addiction and depression in the nucleus accumbens in both rodents and humans. ZF has been engineered to recognize DNA-binding domain to a given catalytic site, which allows gene-targeted transcriptional regulation at a locus of interest. Based on this result, it selectively activated the FosB gene in mouse nucleus accumbens with a Herpes Simplex viral vector, thus mimicking this unique pathological modification of histone in depressed humans. Animals were studied under the paradigm of chronic social defeat stress. The results showed that Herpes Simplex viral vector-injected mice showed a depressive-like behavior (Heller et al., 2014). In the same way, Sun et al. (2015) demonstrated that the ATP-dependent chromatin remodeling can be a novel therapeutic target in depressed patients to mediate depressive-like behavior. These results represent a promising area of research in the treatment of patients with MDD.

Conclusion

The described studies indicate that neurological disorders, including AD, epilepsy, and MDD, are complex multifactorial processes that include chronic alterations in the structure and function of neural circuitry. GDNF and its GFR α family receptors play a crucial role in cognition including spatial memory retention and pattern separation, two behavioral traits associated with hippocampal dysfunction during aging and AD. On the other hand, the strategy of locally increasing GDNF levels in the hippocampus could represent a possible way of suppressing status epilepticus in TLE and diminish symptoms in MDD.

GDNF gene therapy in the hippocampus has the potential to benefit these disorders by increasing GDNF levels and promoting a healthy neuron environment and neural plasticity. In line with this, the ability to regulate transgene expression to the newly engineered vectors as the adenoviral-based one or ECB could constitute a significant advantage for long-term treatments, or for those approaches circumscribed to a temporary window of expression.

Cell reprogramming emerges as a potentially effective strategy to attenuate age-related dysfunctions in the central nervous system, including neurodegenerative diseases.

Review

Moreover, epigenome remodeling shows enormous potential as an innovative therapeutic approach to treat many human diseases, including TLE and MDD.

It is expected that in the coming years, cell reprogramming makes it possible to implement personalized regenerative medicine for neurological disorders.

Acknowledgments: *The authors are deeply indebted to the late Ms. Rosana del Cid for editorial assistance. RC is a professional translator of the Argentine Research Council (CONICET).*

Author contributions: *PC wrote the section of EPIGENETIC AND CELL REPROGRAMMING. MCM and ML wrote the GENE THERAPY section. RGG and GRM wrote about neurological disorders. GRM wrote the CONCLUSION and prepared the figure. All authors approved the final version of the manuscript.*

Conflicts of interest: *GRM and RGG are career researchers of the Argentine Research Council (CONICET). PC, MCM and ML are recipients of a CONICET doctoral fellowship. The authors declare no conflicts of interest.*

Financial support: *This work was supported by grant #PICT16-1070 from the Argentine Agency for the Promotion of Science and Technology (ANCYP) to GRM.*

Copyright license agreement: *The Copyright License Agreement has been signed by all authors before publication.*

Plagiarism check: *Checked twice by iThenticate.*

Peer review: *Externally peer reviewed.*

Open access statement: *This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.*

References

- Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megias D, Dominguez O, Martinez D, Manzanares M, Ortega S, Serrano M (2013) Reprogramming in vivo produces teratomas and iPS cells with totipotency features. *Nature* 502:340-345.
- Adams B, Von Ling E, Vaccarella L, Ivy GO, Fahnestock M, Racine RJ (1998) Time course for kindling-induced changes in the hilar area of the dentate gyrus: reactive gliosis as a potential mechanism. *Brain Res* 804:331-336.
- Adams B, Szazgar M, Osehobo P, Van der Zee CEEM, Diamond J, Fahnestock M, Racine RJ (1997) Nerve growth factor accelerates seizure development, enhances mossy fiber sprouting, and attenuates seizure-induced decreases in neuronal density in the kindling model of epilepsy. *J Neurosci* 17:5288-5296.
- Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR (2011) Identification of novel GDNF isoforms and cis-antisense GDNF gene and their regulation in human middle temporal gyrus of Alzheimer disease. *J Biol Chem* 286:45093-45102.
- Allen NJ, Barres BA (2009) Neuroscience: glia-more than just brain glue. *Nature* 457:675-677.
- Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFR α 3-RET receptor complex. *Neuron* 21:1291-302.
- Ben-Ari Y, Tremblay E, Ottersen OP (1980) Injections of kainic acid into the amygdaloid complex of the rat: an electrographic, clinical and histological study in relation to the pathology of epilepsy. *Neuroscience* 5:515-528.
- Bengzon J, Kokaia Z, Elmer E, Nanobashvili A, Kokaia M, Lindvall O (1997) Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. *Proc Natl Acad Sci U S A* 94:10432-10437.
- Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. *Trends Pharmacol Sci* 28:68-74.
- Bonafina A, Trincherro MF, Ríos AS, Bekinschtein P, Schinder AF, Paratcha G, Ledda F (2019) GDNF and GFR α 1 are required for proper integration of adult-born hippocampal neurons. *Cell Rep* 29:4308-4319.
- Bourque MJ, Trudeau LE (2000) GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. *Eur J Neurosci* 12:3172-3180.

- Buckmaster PS (2004) Laboratory animal models of temporal lobe epilepsy. *Comp Med* 54:473-485.
- Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI (2015) The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease. *Aging Dis* 6:331-341.
- Campbell KH, McWhir J, Ritchie WA, Wilmut I (1996) Sheep cloned by nuclear transfer from a cultured cell line. *Nature* 380:4-66.
- Capetian P, Azmitia L, Pauly MG, Krajka V, Stengel F, Bernhardt EM, Klett M, Meier B, Seibler P, Stanslowsky N, Moser A, Knopp A, Gillissen-Kaesbach G, Nikkhah G, Wegner F, Döbrössy M, Klein C (2016) Plasmid-based generation of induced neural stem cells from adult human fibroblasts. *Front Cell Neurosci* 10:245.
- Cavazos JE, Sutula TP (1990) Progressive neuronal loss induced by kindling: a possible mechanism for mossy fiber synaptic reorganization and hippocampal sclerosis. *Brain Res* 527:1-6.
- Cavazos JE, Golarai G, Sutula TP (1991) Mossy fiber sprouting reorganization induced by kindling: Time course of development, progression, and permanence. *J Neurosci* 11:2795-2803.
- Cavazos JE, Das I, Sutula TP (1994) Neuronal loss induced in limbic pathways by kindling: Evidence for induction of hippocampal sclerosis by repeated brief seizures. *J Neurosci* 14:3106-3121.
- Chen Y, Ai Y, Slevin JR, Maley BE, Gash DM (2005) Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. *Exp Neurol* 196:87-95.
- Coll L, Rodriguez SS, Goya RG, Morel GR (2020) A regulatable adenovector system for GDNF and GFP delivery in the rat hippocampus. *Neuropeptides* 83:102072.
- Connor B, Firmin E, McCaughey-Chapman A, Monk R, Lee K, Liot S, Geiger J, Rudolph C, Jones K (2018) Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNA. *Heliyon* 4:e00918.
- Cosolo WC, Martinello P, Louis WJ, Christophidis N (1989) Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. *Am J Physiol* 256:R443-447.
- Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51:987-1000.
- Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiovaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sariola H, Pachnis V (1996) GDNF signalling through the Ret receptor tyrosine kinase. *Nature* 381:789-793.
- Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. *Brain Res Bull* 143:155-170.
- Falahi F, Sgro A, Blancafort P (2015) Epigenome engineering in cancer: fairy tale or a realistic path to the clinic. *Front Oncol* 5:22.
- Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, Teixeira AL (2015) Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. *J Alzheimers Dis* 46:423-429.
- French ED, Aldinio C, Schwartz R (1982) Intrahippocampal kainic acid, seizures and local neuronal degeneration: relationships assessed in unanesthetized rats. *Neuroscience* 7:2525-2536.
- Gerlai R, Mcnamara A, Armanini M, Ross J, Phillips HS (2001) Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. *Eur J Neurosci* 14:1153-1163.
- Ghasemi-Kasman M, Shojaei A, Gol M, Moghadamnia AA, Baharvand H, Javan M (2018) miR-302/367-induced neurons reduce behavioral impairment in an experimental model of Alzheimer's disease. *Mol Cell Neurosci* 86:50-57.
- Ghribi O, Herman MM, Forbes MS, DeWitt DA Savory J (2001) GDNF protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. *Neurobiol Dis* 5:764-773.
- Goddard GV (1967) Development of epileptic seizures through brain stimulation at low intensity. *Nature* 214:1020-1021.
- Goddard GV, McIntyre DC, Leech CK (1969) A permanent change in brain function resulting from daily electrical stimulation. *Exp Neurol* 5:295-330.
- Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ (1999) Learning enhances adult neurogenesis in the hippocampal formation. *Nat Neurosci* 2:260-265.

- Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G (2014) In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. *Cell Stem Cell* 14:188-202.
- Gurdon JB (1962) The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. *J Embryol Exp Morphol* 10:622-640.
- Hawkins KE, Duchon M (2019) Modelling mitochondrial dysfunction in Alzheimer's disease using human induced pluripotent stem cells. *World J Stem Cells* 11:236-253.
- Heller EA, Cates HM, Peña CJ, Sun H, Shao N, Feng J, Golden SA, Herman JP, Walsh JJ, Mazei-Robison M, Ferguson D, Knight S, Gerber MA, Nievera C, Han MH, Russo SJ, Tamminga CS, Neve RL, Shen L, Zhang HS, et al. (2014) Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. *Nat Neurosci* 17:1720-1727.
- Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S (2007) Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. *J Pharmacol Exp Ther* 21:148-157
- Honig LS, Rosenberg RN (2000) Apoptosis and neurologic disease. *Am J Med* 102:317-330.
- Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, Gao L, Shen L, Huang Y, Xie G, Zhao H, Jin Y, Tang B, Yu Y, Zhao J, Pei G (2015) Direct conversion of normal and Alzheimer's Disease human fibroblasts into neuronal cells by small molecules. *Cell Stem Cell* 17:204-212.
- Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, Mackerlova L, Lile JD, Collins F, Hoffer BJ (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. *Brain Res Bull* 36:425-432.
- Ibanez CF, Andressoo JO (2017) Biology of GDNF and its receptors- Relevance for disorders of the central nervous system. *Neurobiol Dis* 97:80-89.
- Ibanez CF (2013) Structure and physiology of the RET receptor tyrosine kinase. *Cold Spring Harb Perspect Biol* 5:1-10
- Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LSB (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 482:216-220.
- Kajitani N, Hisaoka-Nakashima K, Okada-Tsuchioka M, Hosoi M, Yokoe T, Morioka N, Nakata Y, Takebayashi M (2015) Fibroblast growth factor 2 mRNA expression evoked by amitriptyline involves extra-cellular signal-regulated kinase-dependent early growth response 1 production in rat primary cultured astrocytes. *J Neurochem* 135:27-37.
- Kanter-Schlifke I, Fjord-Larsen L, Kusk P, Ängehagen M, Wahlberg L, Kokaia M (2009) GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. *Exp Neurol* 216:413-419.
- Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. *Mol Ther* 15:1106-1113.
- Keuter JIH, Luiten PGM, Fuchs E (2003) Preservation of hippocampal neuron numbers in aged rhesus monkeys. *Neurobiol Aging* 24:157-165.
- Kim J, Efe JA, Zhu S, Talantova M, Yuan X, Wang S, Lipton SA, Zhang K, Ding S (2011) Direct reprogramming of mouse fibroblasts to neural progenitors. *Proc Natl Acad Sci U S A* 108:7838-7843.
- Koehl M, Abrous DN (2011) A new chapter in the field of memory: adult hippocampal neurogenesis. *Eur J Neurosci* 33:1101-1114
- Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Crendon DJ, Johnson EM Jr, Milbrandt J (1996) Neurturin, a relative of glial-cell-line-derived neurotrophic factor. *Nature* 384:467-470.
- Ledda F (2007) Ligand-induced cell adhesion as a new mechanism to promote synapse formation. *Cell Adh Migr* 1:137-139
- Lehmann M, Canatelli-Mallat M, Chiavellini P, Morel GR, Reggiani PC, Hereñú CB, Goya RG (2019) Regulatable adenovector harboring the GFP and Yamanaka genes for implementing regenerative medicine in the brain. *Gene Ther* 26:432-440.
- Lehmann M, Canatelli-Mallat M, Chiavellini P, Cónsole GM, Gallardo MD, Goya RG (2019) Partial reprogramming as an emerging strategy for safe induced cell generation and rejuvenation. *Curr Gene Ther* 19:248-254.
- Leuner B, Gould E, Shors TJ (2006) Is there a link between adult neurogenesis and learning? *Hippocampus* 16:216-224.
- Lévesque M, Avoli M (2013) The kainic acid model of temporal lobe epilepsy. *Neurosci Biobehav Rev* 37:2887-2899.
- Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 260:1130-1132.
- Lin PY, Tseng PT (2015) Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a meta-analytic study. *J Psychiatr Res* 63:20-27.
- Lu D, Bonkowski MS, Yang JH, Zhou S, Hoffmann EM, Karg MM, Schultz MB, Kane AE, Davidsohn N, Korobkina E, Chwalek K, Rajman LA, Church GM, Hochedlinger K, Gladyshev VN, Horvath S, Levine ME, Gregory-Ksander MS, Ksander BR, He Z, et al. (2020) Reprogramming to recover youthful epigenetic information and restore vision. *Nature* 588:124-129.
- Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M (2012) Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. *Proc Natl Acad Sci U S A* 109:2527-2532.
- Marco S, Canudas AM, Canal JM, Gavald N, Perez-Navarro E, Alberch J (2002) Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. *Exp Neurol* 174:243-252.
- Matsunaga W, Isobe K, Shirokawa T (2006) Involvement of neurotrophic factors in aging of noradrenergic innervations in hippocampus and frontal cortex. *Neurosci Res* 54:313-318.
- McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009) A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. *J Psychiatry Neurosci* 34:41-54.
- Mertens J, Marchetto MC, Bardy C, Gage FH (2016) Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. *Nat Rev Neurosci* 17:424-437.
- Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, et al. (1998) Persephin, a novel neurotrophic factor related to GDNF and neurturin. *Neuron* 20:245-53.
- Moghadam FH, Alaie H, Karbalaie K, Tanhaei S, Nasr Esfahani MH, Baharvand H (2009) Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in Alzheimerian rats. *Differentiation* 78:59-68.
- Morel GR, Andersen T, Pardo J, Zuccolilli GO, Cambiaggi VL, Hereñú CB, Goya RG (2015) Cognitive impairment and morphological changes in the dorsal hippocampus of very old female rats. *Neuroscience* 303:189-199.
- Nanobashvili A, Melin E (2018) Unilateral ex vivo gene therapy by GDNF in epileptic rats. *Gene Therapy* 26:65-74.
- Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, Buisson A (2001) Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. *J Neurosci* 21:3024-3033.
- Nitecka L, Tremblay E, Charton G, Bouillot JP, Berger M, Ben-Ari Y (1984) Maturation of kainic acid seizure-brain damage syndrome in the rat. II. Histopathological sequelae. *Neuroscience* 13:1073-1094.
- Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, Li M, Lam D, Kurita M, Beyret E, Araoka T, Vazquez-Ferrer E, Donoso D, Roman JL, Xu J, Rodriguez Esteban C, Nuñez G, Nuñez Delicado E, Campistol JM, Guillen I, et al. (2016) In vivo amelioration of age-associated hallmarks by partial reprogramming. *Cell* 167:1719-1733.
- Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, Soejima H, Moriawaki H, Yamanaka S, Woltjen K, Yamada Y (2014) Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. *Cell* 156:663-677.
- Palm K, Belluardo N, Metsis M, Timmusk T (1998) Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. *J Neurosci* 18:1280-1296.
- Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, Südhof TC, Wernig M (2011) Induction of human neuronal cells by defined transcription factors. *Nature* 476:220-223.

Review

- Paolone G, Falcicchia C, Lovisari F, Kokaia X, Bell WJ, Fradet T, Barbieri M, Wahlberg LU, Emerich DF, Simonato M (2019) Long-term, targeted delivery of GDNF from encapsulated cells is neuroprotective and reduces seizures in the pilocarpine model of epilepsy. *J Neurosci* 39:2144-2156.
- Paratcha G, Ledda F, Ibanez CF (2003) The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. *Cell* 113:867-879.
- Paratcha G, Ibanez CF (2002) Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme. *Curr Opin Neurobiol* 12:542-549.
- Paratcha G, Ledda F, Baars L, Couplier M, Besset V, Besset V, Anders J, Scott R, Ibanez CF (2001) Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. *Neuron* 29:171-184.
- Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH (1997) Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. *J Neurosci* 17:3727-3738.
- Pavletich NP, Pabo CO (1991) Zinc finger-DNA recognition: crystal structure of a Zif268 DNA complex at 2.1 Å. *Science* 252:809-817.
- Pelleymounter MA, Cullen MJ, Baker MB, Healy D (1999) Glial cell-line derived neurotrophic factor (GDNF) improves spatial learning in aged fisher 344 rats. *Psychobiology* 27:397-401.
- Pertusa M, García-Matas S, Mammari H, Adell A, Rodrigo T, Mallet J, Cristòfol R, Sarkis C, Sanfeliu C (2008) Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. *Neurobiol Aging* 29:1366-1379.
- Portela A, Esteller M (2010) Epigenetic modifications and human disease. *Nat Biotechnol* 28:1057-1068.
- Querfurth HW, LaFerla FM (2010) Alzheimer's disease. *N Engl J Med* 362:329-344.
- Raman S, Brookhouser N, Brafman DA (2020) Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. *Neurobiol Dis* 138:104788.
- Rapp PR, Amaral DG (1989) Evidence for task-dependent memory dysfunction in the aged monkey. *J Neurosci* 9:3568-3576.
- Rapp PR, Gallagher M (1996) Preserved neuron number in the hippocampus of aged rats with spatial learning deficits. *Proc Natl Acad Sci U S A* 93:9926-9930.
- Revilla S, Sunol C, Garcia-Mesa Y, Gimenez-Llort L, Sanfeliu C, Cristofol R (2014) Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. *Neuropharmacology* 81:55-63.
- Revilla S, Ursulet S, Álvarez-López MJ, Castro-Freire M, Perpiñá U, García-Mesa Y, Bortolozzi A, Giménez-Llort L, Kaliman P, Cristòfol R, Sarkis C, Sanfeliu C (2014) Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. *CNS Neurosci Ther* 20:961-972.
- Reyes-García SZ, Scorza CA, Araújo NS, Ortiz-Villatoro NN, Jardim AP, Centeno R, Targas Yacubian EM, Faber J, Esper A, Cavalheiro EA (2018) Different patterns of epileptiform-like activity are generated in the sclerotic hippocampus from patients with drug-resistant temporal lobe epilepsy. *Sci Rep* 8:7116.
- Rodríguez-Matellán A, Alcazar N, Hernández F, Serrano M, Ávila J (2020) In vivo reprogramming ameliorates aging features in dentate gyrus cells and improves memory in mice. *Stem Cell Reports* 15:1056-1066.
- Roopra A, Huang Y, Dingledine R (2001) Neurological disease: listening to gene silencers. *Mol Interv* 1:219-228.
- Rowland HA, Hooper NM, Kellett KAB (2018) Modelling sporadic Alzheimer's disease using induced pluripotent stem cells. *Neurochem Res* 43:2179-2198.
- Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging* 27:372-384.
- Siegel GJ, Chauhan NB (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease brain. *Brain Res Brain Res* R33:199-227.
- Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC (2013) Progress in gene therapy for neurological disorders. *Nat Rev Neurol* 9:277-291.
- Sperk G (1994) Kainic acid seizures in the rat. *Prog Neurobiol* 42:1-32.
- Sun H, Damez-Werno DM, Scobie KN, Shao NY, Dias C, Rabkin J, Koo JW, Korb E, Bagot RC, Ahn FH, Cahill ME, Labonté B, Mouzon E, Heller EA, Cates H, Golden SA, Gleason K, Russo SJ, Andrews S, Neve R, et al. (2015) Acf chromatin-remodeling complex mediates stress-induced depressive-like behavior. *Nat Med* 21:1146-1153.
- Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:663-676.
- Tincer G, Mashkaryan V, Bhattarai P, Kizil C (2016) Neural stem/progenitor cells in Alzheimer's disease. *Yale J Biol Med* 89:23-35.
- Trupp M, Scott R, Whittemore SR, Ibañez, CF (1999) Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. *J Biol Chem* 274:20885-20894.
- Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, Suzuki T, Miyata N, Watanabe Y (2011) Epigenetic status of GDNF in the ventral striatum determines susceptibility and adaptation to daily stressful events. *Neuron* 69:59-372.
- Urdinguio RG, Sanchez-Mut JV, Esteller M (2009) Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. *Lancet Neurol* 8:1056-1072.
- Voikar V, Vasar E, Rauvala H (2004) Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. *Genes Brain Behav* 3:27-38.
- Wang CY, Yang F, He X, Chow A, Du J, Russell JT, Lu B (2001). Ca²⁺ binding protein frequenin mediates GDNF-induced potentiation of Ca²⁺ channels and transmitter release. *Neuron* 32:99-112.
- Weng N, Sun J, Kuang S, Lan H, He Q, Yang H, Zhang L, Xue H (2020) MicroRNA-451 aggravates kainic acid-induced seizure and neuronal apoptosis by targeting GDNF. *Curr Neurovasc Res* 17:50-57.
- West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. *Lancet* 344:769-772.
- Winięcka-Klimek M, Smolarz M, Walczak MP, Zieba J, Hulas-Bigoszewska K, Kmiecik B, Piaskowski S, Rieske P, Grzela DP, Stoczynska-Fidelus E (2015) SOX2 and SOX2-MYC reprogramming process of fibroblasts to the neural stem cells compromised by senescence. *PLoS One* 10:e0141688.
- Wu C, Morris JR (2001) Genes, genetics, and epigenetics: a correspondence. *Science* 293:1103-1105.
- Yang H, Zhang L, An J, Zhang Q, Liu C, He B, Hao DJ (2017) MicroRNA-mediated reprogramming of somatic cells into neural stem cells or neurons. *Mol Neurobiol* 54:1587-1600.
- Yilmazer-Hanke DM, Wolf HK, Schramm J, Elger CE, Wiestler OD, Blümcke I (2000) Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy. *J Neuropathol Exp Neurol* 59:907-920.
- Yoo Y, Lee C, Lee U, Kim Y (2006) Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus. *Exp Neurol* 200:407-417.
- Zhang X, Zhao L, Wu J, Dong H, Xu F, Gong G, Hu Y (2012) Current advances in vehicles for brain gene delivery. *Curr Gene Ther* 12:423-436.
- Zhang X, Zhang Z, Xie C, Xi G, Zhou H, Zhang Y, Sha W (2008) Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry* 32:886-890.

C-Editors: Zhao M, Qiu Y; T-Editor: Jia Y